163 related articles for article (PubMed ID: 22532859)
41. Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia.
Handels RLH; Wimo A; Dodel R; Kramberger MG; Visser PJ; Molinuevo JL; Verhey FRJ; Winblad B
J Alzheimers Dis; 2017; 60(4):1477-1487. PubMed ID: 29081416
[TBL] [Abstract][Full Text] [Related]
42. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.
Morris JC
Arch Neurol; 2012 Jun; 69(6):700-8. PubMed ID: 22312163
[TBL] [Abstract][Full Text] [Related]
43. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
44. An MRI-based index to measure the severity of Alzheimer's disease-like structural pattern in subjects with mild cognitive impairment.
Spulber G; Simmons A; Muehlboeck JS; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Spenger C; Lovestone S; Wahlund LO; Westman E;
J Intern Med; 2013 Apr; 273(4):396-409. PubMed ID: 23278858
[TBL] [Abstract][Full Text] [Related]
45. Novel Blood Biomarkers that Correlate with Cognitive Performance and Hippocampal Volumetry: Potential for Early Diagnosis of Alzheimer's Disease.
Hudd F; Shiel A; Harris M; Bowdler P; McCann B; Tsivos D; Wearn A; Knight M; Kauppinen R; Coulthard E; White P; Conway ME
J Alzheimers Dis; 2019; 67(3):931-947. PubMed ID: 30689581
[TBL] [Abstract][Full Text] [Related]
46. Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography.
Beyer L; Brendel M; Scheiwein F; Sauerbeck J; Hosakawa C; Alberts I; Shi K; Bartenstein P; Ishii K; Seibyl J; Cumming P; Rominger A;
J Alzheimers Dis; 2020; 74(1):101-112. PubMed ID: 31985461
[TBL] [Abstract][Full Text] [Related]
47. Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia.
Zhao A; Li Y; Yan Y; Qiu Y; Li B; Xu W; Wang Y; Liu J; Deng Y
Transl Neurodegener; 2020 Aug; 9(1):30. PubMed ID: 32741361
[TBL] [Abstract][Full Text] [Related]
48. A comparison of resting state EEG and structural MRI for classifying Alzheimer's disease and mild cognitive impairment.
Farina FR; Emek-Savaş DD; Rueda-Delgado L; Boyle R; Kiiski H; Yener G; Whelan R
Neuroimage; 2020 Jul; 215():116795. PubMed ID: 32278090
[TBL] [Abstract][Full Text] [Related]
49. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
[TBL] [Abstract][Full Text] [Related]
50. Volumetric and visual rating of magnetic resonance imaging scans in the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease.
Shen Q; Loewenstein DA; Potter E; Zhao W; Appel J; Greig MT; Raj A; Acevedo A; Schofield E; Barker W; Wu Y; Potter H; Duara R
Alzheimers Dement; 2011 Jul; 7(4):e101-8. PubMed ID: 21784342
[TBL] [Abstract][Full Text] [Related]
51. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease.
Waragai M; Okamura N; Furukawa K; Tashiro M; Furumoto S; Funaki Y; Kato M; Iwata R; Yanai K; Kudo Y; Arai H
J Neurol Sci; 2009 Oct; 285(1-2):100-8. PubMed ID: 19552926
[TBL] [Abstract][Full Text] [Related]
52. Screening and treatment for Alzheimer's disease: predicting population-level outcomes.
Furiak NM; Kahle-Wrobleski K; Callahan C; Klein TM; Klein RW; Siemers ER
Alzheimers Dement; 2012 Jan; 8(1):31-8. PubMed ID: 22265589
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease.
Lee SA; Sposato LA; Hachinski V; Cipriano LE
Alzheimers Res Ther; 2017 Mar; 9(1):18. PubMed ID: 28302164
[TBL] [Abstract][Full Text] [Related]
54. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.
Ruan Q; D'Onofrio G; Sancarlo D; Bao Z; Greco A; Yu Z
BMC Geriatr; 2016 May; 16():104. PubMed ID: 27184250
[TBL] [Abstract][Full Text] [Related]
55. Intrinsic functional connectivity, CSF biomarker profiles and their relation to cognitive function in mild cognitive impairment.
Matura S; Köhler J; Reif A; Fusser F; Karakaya T; Scheibe M; Ehret F; Hartmann D; Kang JS; Mayer C; Prvulovic D; Pantel J
Acta Neuropsychiatr; 2020 Aug; 32(4):206-213. PubMed ID: 31801648
[TBL] [Abstract][Full Text] [Related]
56. Amyloid pathology in the progression to mild cognitive impairment.
Insel PS; Hansson O; Mackin RS; Weiner M; Mattsson N;
Neurobiol Aging; 2018 Apr; 64():76-84. PubMed ID: 29353101
[TBL] [Abstract][Full Text] [Related]
57. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation.
Cooper KL; Meng Y; Harnan S; Ward SE; Fitzgerald P; Papaioannou D; Wyld L; Ingram C; Wilkinson ID; Lorenz E
Health Technol Assess; 2011 Jan; 15(4):iii-iv, 1-134. PubMed ID: 21276372
[TBL] [Abstract][Full Text] [Related]
58. Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer's disease.
Huang M; Yang W; Feng Q; Chen W;
Sci Rep; 2017 Jan; 7():39880. PubMed ID: 28079104
[TBL] [Abstract][Full Text] [Related]
59. The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD.
Bruno D; Gleason CE; Koscik RL; Pomara N; Zetterberg H; Blennow K; Johnson SC
Int J Geriatr Psychiatry; 2019 Mar; 34(3):415-419. PubMed ID: 30430632
[TBL] [Abstract][Full Text] [Related]
60. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Suh CH; Kim KW; Park SH; Kim SY; Woo DC; Shin S; Pyo J; Shinagare AB; Ramaiya NH; Lim YS
AJR Am J Roentgenol; 2018 Feb; 210(2):W63-W69. PubMed ID: 29091004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
